These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 8782082)

  • 21. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
    Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
    Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C
    Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal peptide receptor expression in immortalized LHRH neurons.
    Olcese J; McArdle CA; Middendorff R; Greenland K
    J Neuroendocrinol; 1997 Dec; 9(12):937-43. PubMed ID: 9468019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
    Vertongen P; Camby I; Darro F; Kiss R; Robberecht P
    Neuropeptides; 1996 Oct; 30(5):491-6. PubMed ID: 8923513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.
    Oka H; Jin L; Reubi JC; Qian X; Scheithauer BW; Fujii K; Kameya T; Lloyd RV
    Am J Pathol; 1998 Dec; 153(6):1787-96. PubMed ID: 9846969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates growth hormone release from GH3 cells through type II PACAP receptor.
    Murakami Y; Koshimura K; Yamauchi K; Nishiki M; Tanaka J; Furuya H; Miyake T; Kato Y
    Regul Pept; 1995 Mar; 56(1):35-40. PubMed ID: 7770631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue-specific and developmental expression of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in rat brain.
    D'Agata V; Cavallaro S; Stivala F; Canonico PL
    Eur J Neurosci; 1996 Feb; 8(2):310-8. PubMed ID: 8714702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Eur J Pharmacol; 1995 Dec; 287(1):7-11. PubMed ID: 8666028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pituitary adenylate cyclase-activating polypeptide expression and modulation of neuronal excitability in guinea pig cardiac ganglia.
    Braas KM; May V; Harakall SA; Hardwick JC; Parsons RL
    J Neurosci; 1998 Dec; 18(23):9766-79. PubMed ID: 9822736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
    Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
    Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor.
    Sano H; Miyata A; Horio T; Nishikimi T; Matsuo H; Kangawa K
    Regul Pept; 2002 Nov; 109(1-3):107-13. PubMed ID: 12409222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pituitary adenylate cyclase-activating polypeptide].
    Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
    Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.
    Vertongen P; Ciccarelli E; Woussen-Colle MC; De Neef P; Robberecht P; Cauvin A
    Endocrinology; 1994 Oct; 135(4):1537-42. PubMed ID: 7925114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas.
    Robberecht P; Vertongen P; Velkeniers B; de Neef P; Vergani P; Raftopoulos C; Brotchi J; Hooghe-Peters EL; Christophe J
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1235-9. PubMed ID: 8077316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.